Publication | Open Access

A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients

Tumor ImmunologyCancer ImmunosurveillancePhase Ii TrialMedicineMelanomaImmunologyTumor ImmunityTherapeutic VaccineImmune SurveillanceT Cell ImmunityImmunotherapeuticsImmune SystemImmunotherapyRadiation OncologyViral ImmunityMetastatic Melanoma Patients